Sugammadex versus neostigmine reversal of moderate rocuronium-induced neuromuscular blockade in Korean patients
| Autor: | Phillip Phiri, Mi Kyeong Kim, Suk Min Yoon, Young Jin Lim, Tiffany Woo, Kyo Sang Kim, Yon Hee Shim, Hong Seuk Yang, Jin Young Chon |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Neuromuscular Blockade
medicine.medical_specialty Clinical Research Article business.industry medicine.medical_treatment Korean Caucasian Sugammadex Neostigmine lcsh:RD78.3-87.3 Anesthesiology and Pain Medicine lcsh:Anesthesiology Anesthesia Anesthesiology medicine Intubation Neuromuscular blockade Rocuronium business Adverse effect Glycopyrrolate medicine.drug |
| Zdroj: | Korean Journal of Anesthesiology Korean Journal of Anesthesiology, Vol 65, Iss 6, Pp 501-507 (2013) |
| ISSN: | 2005-6419 |
| Popis: | Background: Rapid and complete reversal of neuromuscular blockade (NMB) is desirable at the end of surgery. Sugammadex reverses rocuronium-induced NMB by encapsulation. It is well tolerated in Caucasian patients, providing rapid reversal of moderate (reappearance of T2) rocuronium-induced NMB. We investigated the efficacy and safety of sugam madex versus neostigmine in Korean patients. Methods: This randomized, safety assessor-blinded trial (NCT01050543) included Korean patients undergoing general anesthesia. Rocuronium 0.6 mg/kg was given prior to intubation with maintenance doses of 0.1-0.2 mg/kg as required. Patients received sugammadex 2.0 mg/kg or neostigmine 50 μg/kg with glycopyrrolate 10 μg/kg to reverse the NMB at the reappearance of T2, after the last rocuronium dose. The primary efficacy endpoint was the time from sugammadex or neostigmine administration to recovery of the train-of-four (TOF) ratio to 0.9. The safety of these medications was also assessed. Results: Of 128 randomized patients, 118 had evaluable data (n = 59 in each group). The geometric mean (95% confi dence interval) time to recovery of the TOF ratio to 0.9 was 1.8 (1.6, 2.0) minutes in the sugammadex group and 14.8 (12.4, 17.6) minutes in the neostigmine group (P < 0.0001). Sugammadex was generally well tolerated, with no evidence of residual or recurrence of NMB; four patients in the neostigmine group reported adverse events possibly indicative of inadequate NMB reversal. Conclusions: Sugammadex was well tolerated and provided rapid reversal of moderate rocuronium-induced NMB in Korean patients, with a recovery time 8.1 times faster than neostigmine. These results are consistent with those reported for Caucasian patients. (Korean J Anesthesiol 2013; 65: 501-507) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|